Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium
Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )
11 Sep 2022

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA
Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )
11 Sep 2022

New era of early cancer detection blood tests on the horizon

Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA
New era of early cancer detection blood tests on the horizon ( Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA )
11 Sep 2022

Hyperthermic intraperitoneal chemo for locally advanced colon cancer

Dr Álvaro Arjona-Sánchez- Reina Sofia University Hospital, Cordoba, Spain
Hyperthermic intraperitoneal chemo for locally advanced colon cancer ( Dr Álvaro Arjona-Sánchez- Reina Sofia University Hospital, Cordoba, Spain )
11 Sep 2022

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )
11 Sep 2022

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA
HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Sep 2022

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy

Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht, Netherlands
Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy ( Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht, Netherlands )
11 Sep 2022

Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19

Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA
Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19 ( Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA )
11 Sep 2022

Olaparib continues to show positive results in advanced ovarian cancer - 7 year data

Prof Paul DiSilvestro - Women & Infants Hospital, Providence, USA
Olaparib continues to show positive results in advanced ovarian cancer - 7 year data ( Prof Paul DiSilvestro - Women & Infants Hospital, Providence, USA )
10 Sep 2022

How air pollution may trigger lung cancer in never-smokers

Prof Charles Swanton - Francis Crick Institute, London, England
How air pollution may trigger lung cancer in never-smokers ( Prof Charles Swanton - Francis Crick Institute, London, England )
10 Sep 2022

Tumour-infiltrating lymphocyte treatment for advanced melanoma

Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands
Tumour-infiltrating lymphocyte treatment for advanced melanoma ( Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )
10 Sep 2022

Nirogacestat success for desmoid tumours

Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany
Nirogacestat success for desmoid tumours ( Dr Bernd Kasper -  Universitätsmedizin Mannheim, Mannheim, Germany )
10 Sep 2022